(Q72660731)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8262732%20AND%20SRC:MED&resulttype=core&format=json

28 October 2019

title

Phase II evaluation of the sulfonylurea LY186,641 in men with hormone independent metastatic prostate cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8262732%20AND%20SRC:MED&resulttype=core&format=json

28 October 2019

author name string

G Wilding

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8262732%20AND%20SRC:MED&resulttype=core&format=json

28 October 2019

G Grindey

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8262732%20AND%20SRC:MED&resulttype=core&format=json

28 October 2019

N Munshi

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8262732%20AND%20SRC:MED&resulttype=core&format=json

28 October 2019

D Seitz

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8262732%20AND%20SRC:MED&resulttype=core&format=json

28 October 2019

L Einhorn

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8262732%20AND%20SRC:MED&resulttype=core&format=json

28 October 2019

publication date

1 May 1993

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8262732%20AND%20SRC:MED&resulttype=core&format=json

Investigational New Drugs

28 October 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8262732%20AND%20SRC:MED&resulttype=core&format=json

28 October 2019

volume

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8262732%20AND%20SRC:MED&resulttype=core&format=json

28 October 2019

issue

2-3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8262732%20AND%20SRC:MED&resulttype=core&format=json

28 October 2019

page(s)

203-205

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8262732%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/bf00874156

28 October 2019

exact match

0 references

cites work

Phase I clinical study of N-[(4-chlorophenyl)amino]carbonyl-2,3-dihydro-1H-indene-5-sulfonamide (LY186641)

1 reference

12 December 2020

Clinical pharmacology of a novel diarylsulfonylurea anticancer agent

1 reference

12 December 2020

Inhibition of PAIII Rat Prostatic Adenocarcinoma Growth and Metastasis by a New Diarylsulfonylurea Antitumor Agent, LY181984

1 reference

12 December 2020

Cancer statistics, 1991.

1 reference

12 December 2020

Effect of antitumor diarylsulfonylureas on in vivo and in vitro mitochondrial structure and functions.

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF00874156

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8262732%20AND%20SRC:MED&resulttype=core&format=json

28 October 2019

1 reference